This finding has significant clinical relevance, as the Y537S mutation status is associated with a higher degree of resistance (relative to other ESR1 LBD mutations) to nearly all endocrine therapies clinically used in the treatment of ERα+ breast cancer and as development of drugs that preferentially target the Y537S mutation remains an acute unmet clinical need. This evidence concerns the gene ESR1 and breast carcinoma.